Cencora Reports Strong Q4 Revenue Growth and Dividend Increase

Cencora ( (COR) ) just unveiled an announcement.

On November 5, 2025, Cencora reported its fiscal 2025 fourth quarter and year-end results, highlighting a 5.9% increase in fourth-quarter revenue to $83.7 billion and a 9.3% rise in annual revenue to $321.3 billion. Despite a GAAP diluted EPS loss of $1.75 in the fourth quarter, the adjusted EPS increased to $3.84. The company also raised its quarterly dividend by 9% and its long-term guidance, reflecting confidence in continued growth driven by strategic acquisitions and a focus on digital transformation. These results underscore Cencora’s strengthened position in the healthcare market and its commitment to driving stakeholder value.

The most recent analyst rating on (COR) stock is a Hold with a $345.00 price target. To see the full list of analyst forecasts on Cencora stock, see the COR Stock Forecast page.

Spark’s Take on COR Stock

According to Spark, TipRanks’ AI Analyst, COR is a Neutral.

Cencora’s overall stock score is driven by strong earnings performance and positive guidance, which are offset by high leverage and valuation concerns. The technical indicators suggest bullish momentum, but caution is advised due to overbought signals. The company’s financial performance shows improvement, yet high debt levels and declining free cash flow remain risks.

To see Spark’s full report on COR stock, click here.

More about Cencora

Cencora, Inc. operates in the healthcare industry, focusing on pharmaceutical distribution and specialty healthcare solutions. The company is known for its strategic investments in growth-oriented initiatives, digital transformation, and enhancing its business portfolio, particularly through acquisitions like Retina Consultants of America.

Average Trading Volume: 1,448,336

Technical Sentiment Signal: Buy

Current Market Cap: $66.8B

Learn more about COR stock on TipRanks’ Stock Analysis page.